Hastie R, et al. - Researchers used the Swedish Pregnancy Register and assess the risk of preeclampsia in relation to proton pump inhibitor (PPI) use during pregnancy in a cohort of nulliparous pregnant women delivering from January 2013 to July 2017. For this purpose, they used logistic regression analyses. They estimated the risk by calculating crude and adjusted odds ratios (aOR) with 95% CI. PPI use during pregnancy was reported by 6051 (3.8%) of 157,720 participants. An increased risk of overall preeclampsia and preeclampsia at term was observed in relation to PPI use during any point of pregnancy. However, an attenuated risk of preterm (delivery <37 weeks) preeclampsia and early (delivery <34 weeks) preeclampsia was noted in association with PPI use recorded after 28 gestational weeks. The heterogeneous nature of this condition was reflected. Use of PPIs in close proximity to disease onset may prevent preterm preeclampsia.